Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDO/Survivin Vaccine + Temozolomide in Metastatic Melanoma
NCT01543464Phase 2Terminated
- Start
- May 2012
- Primary completion
- Sep 2016
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of IO102 + IO103 in melanoma. Started May 2012; status: terminated.
02
Drugs
IO102 + IO103
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01543464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01543464.